ALMR vs QTRX
ALMR: Alamar Biosciences is a commercial-stage proteomics company providing ultra-sensitive protein biomarker detection instruments and consumables for research and diagnostics. QTRX: Quanterix develops ultra-sensitive protein detection and spatial tissue analysis platforms for biomarker discovery and early disease diagnostics, with recent FDA breakthrough designation for an Alzheimer's blood test.
Side-by-side fundamentals
| Metric | ALMR | QTRX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $25.12 | $3.84 | |
| Market cap as of 2026-07-23 | $1.8B | $181M | |
| PEG as of 2026-07-23 | n/a | -0.02 | |
| Net margin as of 2026-07-23 | -40.2% | -71.9% | ALMR higher |
| Gross margin as of 2026-07-23 | +56.2% | +44.2% | ALMR higher |
| Operating margin as of 2026-07-23 | -42.2% | -96.9% | ALMR higher |
| ROE as of 2026-07-23 | -39.2% | -35.2% | QTRX higher |
| ROA as of 2026-07-23 | -21.3% | -26.0% | ALMR higher |
| Debt / equity as of 2026-07-23 | 1.32 | 0.00 | QTRX lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | +6.8% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +9.6% | |
| Beta as of 2026-07-23 | -1.39 | 1.04 | |
| 1-year return as of 2026-07-22 close | +14.3% | -23.4% | ALMR higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.